ArticleMolecular biology reports2026
Ellagic acid and gallic acid combination attenuates pulmonary fibrotic responses in vitro: evidence suggesting involvement of the 5-HT2B/Ca²⁺/inflammatory axis.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundPulmonary fibrosis (PF) is a progressive interstitial lung disease driven by aberrant extracellular matrix (ECM) remodeling and alveolar destruction. While serotonin (5-HT) promotes fibrogenesis via the 5-HT2B receptor, pharmacological interventions targeting this specific pathway remain scarce. METHODS AND
resultsUsing a spectrum-effect approach, we screened bioactive phenolic acids from Rosa roxburghii Tratt extracts in a TGF-β1-induced A549 cell model. Evaluating ellagic acid (EA), syringic acid (SA), and gallic acid (GA) both individually and in combination revealed that the EA/GA pairing (EG) yielded the most robust anti-fibrotic activity. Specifically, EG restored E-cadherin expression while suppressing key mesenchymal markers, effectively blunting epithelial-mesenchymal transition (EMT) in vitro. At the signaling level, EG treatment correlated with a downregulation of 5-HT2B-associated pathways, alongside marked reductions in oxidative stress and calcium influx. Our data suggest that EG dampens the Gq-PLCβ-IP3R module, limiting both intracellular calcium mobilization and subsequent NFATc1 activation. Concurrently, we observed a suppression of the CaMKII-dependent NF-κB cascade and its downstream pro-inflammatory targets (TNF-α, IL-6, and COX-2).
conclusionsThese findings indicate that the EG combination alleviates pro-fibrotic responses in A549 cells by disrupting the 5-HT2B/calcium/inflammation axis. Although in vivo validation is required, this plant-derived combination offers a promising multi-targeted therapeutic strategy against pulmonary fibrosis.
Indexed as
Identifiers
42541673What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.